BridgeBio Pharma, Inc. (BBIO)
65.91
+0.56
(+0.86%)
USD |
NASDAQ |
Oct 12, 13:55
BridgeBio Pharma Gross Profit Margin (Quarterly) : 93.68% for June 30, 2026
Gross Profit Margin (Quarterly) Chart
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 93.68% |
| March 31, 2026 | 94.64% |
| December 31, 2025 | 94.27% |
| September 30, 2025 | 93.98% |
| June 30, 2025 | 96.14% |
| March 31, 2025 | 97.15% |
| December 31, 2024 | 51.53% |
| September 30, 2024 | 32.80% |
| June 30, 2024 | 13.65% |
| March 31, 2024 | 99.10% |
| December 31, 2023 | -7.91% |
| September 30, 2023 | 52.65% |
| June 30, 2023 | -17.98% |
| March 31, 2023 | 7.78% |
| Date | Value |
|---|---|
| December 31, 2022 | 8.72% |
| September 30, 2022 | -427.8% |
| June 30, 2022 | 97.72% |
| March 31, 2022 | -37.66% |
| December 31, 2021 | 86.21% |
| September 30, 2021 | 37.97% |
| June 30, 2021 | 94.82% |
| March 31, 2021 | 0.00% |
| December 31, 2020 | 0.00% |
| September 30, 2020 | |
| June 30, 2020 | |
| March 31, 2020 | |
| December 31, 2019 | 0.00% |
| September 30, 2019 | 90.65% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Gross Profit Margin (Quarterly) Benchmarks
| Alnylam Pharmaceuticals, Inc. | 76.88% |
| Pfizer Inc. | 62.94% |
| Ionis Pharmaceuticals, Inc. | 96.13% |
| BioMarin Pharmaceutical, Inc. | 72.27% |
| Vertex Pharmaceuticals, Inc. | 85.37% |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Assets | -62.65% |
| Return on Invested Capital | -80.78% |
| Profit Margin (Quarterly) | -63.97% |
| Operating Margin (Quarterly) | -43.94% |
| Return on Net Operating Assets | -299.8% |